Brief: Arcutis Canada Announces Health Canada Acceptance Of The Supplement To A New Drug Submission For Roflumilast
08/01/2024 14:07
Jan 8 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS CANADA ANNOUNCES HEALTH CANADA ACCEPTANCE OF THE
SUPPLEMENT TO A NEW DRUG SUBMISSION FOR ROFLUMILAST FOAM 0.3%
FOR THE TREATMENT OF SEBORRHEIC DERMATITIS IN INDIVIDUALS 9
YEARS OF AGE AND OLDER
Source text for Eikon: ID:nCNWndYhNa
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf